Toxicities associated with checkpoint inhibitor immunotherapy
Posted: Thu Jan 12, 2017 9:54 pm
A prephase to article -
"Dose modifications and immunosuppressive therapy — General guidelines for the management of immune-related adverse events (irAEs) caused by checkpoint inhibitors are incorporated in the US Food and Drug Administration (FDA) Risk Evaluation and Management Strategies (https://www.hcp.yervoy.com/pdf/rems-man ... -guide.pdf) for ipilimumab. These guidelines are incorporated into recommendations for specific toxicities below. Although the side effects of anti-programmed cell death-1 (PD-1) monoclonal antibodies appear to be less severe than with ipilimumab, a similar approach is expected to apply to other immune checkpoint inhibitors as they become available.
In general, treatment of moderate or severe irAEs requires interruption of the checkpoint inhibitor and the use of corticosteroid immunosuppression. Treatment is based upon the severity of the observed toxicity:
https://www.uptodate.com/contents/toxic ... y#H8575913"
"Dose modifications and immunosuppressive therapy — General guidelines for the management of immune-related adverse events (irAEs) caused by checkpoint inhibitors are incorporated in the US Food and Drug Administration (FDA) Risk Evaluation and Management Strategies (https://www.hcp.yervoy.com/pdf/rems-man ... -guide.pdf) for ipilimumab. These guidelines are incorporated into recommendations for specific toxicities below. Although the side effects of anti-programmed cell death-1 (PD-1) monoclonal antibodies appear to be less severe than with ipilimumab, a similar approach is expected to apply to other immune checkpoint inhibitors as they become available.
In general, treatment of moderate or severe irAEs requires interruption of the checkpoint inhibitor and the use of corticosteroid immunosuppression. Treatment is based upon the severity of the observed toxicity:
https://www.uptodate.com/contents/toxic ... y#H8575913"